<DOC>
	<DOCNO>NCT00482950</DOCNO>
	<brief_summary>This study test efficacy safety PHX1149T combination metformin , glitazone , metformin glitazone subject Type 2 diabetes 12 week . After complete 12 week double blind part study , subject enter open label extension study</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy PHX1149T Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Key Entry Criteria : Type 2 diabetes mellitus , diagnose least 4 month 12 year prior screen . Male nonpregnant , nonlactating ( plan become pregnant study ) female subject BMI 25 48 kg/m2 , inclusive . For India BMI 23 48 kg/m2 , inclusive . Current treatment Type 2 diabetes mellitus stable dose metformin 1500 mg ( high tolerate dose ) , TZD ( label dose ) , metformin + TZD dos use accordance product label least 4 week ( metformin ) 10 week ( TZD ) prior screen ( Visit 1 ) . Fasting plasma glucose 118 220 mg/dL ( 6.6 12.2 mmol/L ) , inclusive ; HbA1c 7.3 % 11.0 % , inclusive ; fast plasma C peptide great 0.26 nmol/L screening . For Argentina allow upper limit HbA1c â‰¤ 10.5 % . For Canada upper limit 10.0 % No Type 1 diabetes mellitus mark diabetic longterm complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>